DalsnaFinance

argenx $ARGX

Health Care

Belgium
Create a scorecard
$912.87
-6.34 (-0.69%)
As of Oct 5, 2026, 5:11 PM EDT
Price history
Loading chart…

argenx (ARGX) is trading down at $912.87 (-0.69%), as of the latest quote. It operates in the Health Care sector.

IPO: May 18, 2017 · $17.00 offering · NASDAQ · View IPO details →

argenx revenue & net income history (FY2019–FY2025)

RevenueNet income
$4.15B$1.72B−$709.6MFY2019 revenue: $78.5MFY2019 net income: −$181.2M'19FY2020 revenue: $41.2MFY2020 net income: −$608.5M'20FY2021 revenue: $497.3MFY2021 net income: −$408.3M'21FY2022 revenue: $410.7MFY2022 net income: −$709.6M'22FY2023 revenue: $1.23BFY2023 net income: −$295.1M'23FY2024 revenue: $2.19BFY2024 net income: $833.0M'24FY2025 revenue: $4.15BFY2025 net income: $1.29B'25
argenx annual financial statements
FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$78.5M$41.2M$497.3M$410.7M$1.23B$2.19B$4.15B
Growth (year over year)—−47.4%+1105.7%−17.4%+198.6%+78.6%+89.6%
Gross profit———$381.3M$1.11B$1.96B$3.70B
Gross margin———92.8%90.4%89.6%89.1%
Operating income−$198.9M−$477.6M−$348.7M−$720.3M−$425.0M−$21.7M$1.05B
Operating margin−253.5%−1158.1%−70.1%−175.4%−34.7%−1.0%25.4%
Net income−$181.2M−$608.5M−$408.3M−$709.6M−$295.1M$833.0M$1.29B
Net margin−231.0%−1475.3%−82.1%−172.8%−24.1%38.0%31.1%
EPS (diluted)−$4.69−$13.40−$7.99−$13.05−$5.16$12.78$19.57
Balance sheet
Cash and equivalents$372.2M$1.22B$1.33B$800.7M$2.05B$1.50B$3.49B
Total assets$1.61B$2.28B$2.85B$3.13B$4.54B$6.20B$8.68B
Total liabilities$429.8M$605.4M$316.1M$320.6M$445.0M$704.2M$1.36B
Shareholders' equity$1.18B$1.67B$2.53B$2.81B$4.10B$5.50B$7.32B
Cash flow
Operating cash flow$151.6M−$398.5M−$606.8M−$862.8M−$420.3M−$82.7M$685.2M
Capital expenditure$1.80M$1.07M$3.62M$837.0K$812.0K$1.80M$6.17M
Free cash flow$149.8M−$399.5M−$610.4M−$863.6M−$421.1M−$84.5M$679.0M

From argenx's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About argenx

Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs.

Source: Wikipedia — Argenx

Headquarters
Zwijnaarde, Belgium From SEC filings, Oct 2026

Recent News (1)

More Health Care stocks

Browse all companies →